Business Overview
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting autoimmune and inflammatory diseases with an emphasis on the innate immune system. The company's two most advanced product candidates, OD-001 and OD-002, are in phase 2a clinical trials and IND-enabling studies, respectively. In May 2026, the company completed its IPO, raising approximately $288.7 million in net proceeds to fund operations and advance its development programs.
Segment Performance
No segment performance data is disclosed in the provided filing text. The company operates as a single clinical-stage business without reportable operating segments.
Forward Guidance
"The Company believes that its existing cash, cash equivalents and marketable securities of $175.7 million as of March 31, 2026, together with the additional net proceeds of $288.7 million received from the IPO, concurrent private placement and the underwriters' exercise of the option to purchase additional shares of common stock, will be sufficient to allow the Company to fund operations at least twelve months from the date that the condensed consolidated financial statements are issued."
Key Risk Factors
The company is clinical-stage with no approved products, no product sales revenue, and a history of substantial net losses, requiring significant additional capital to fund operations. Development of product candidates involves lengthy, expensive preclinical and clinical processes with uncertain outcomes; the company has never completed large-scale or pivotal clinical trials. The company faces substantial competition in drug discovery and development, relies heavily on third parties for clinical trials and manufacturing, and depends on retaining key personnel and obtaining and maintaining adequate intellectual property protection for its candidates.
